NKG2 proteins: Checkpoint targets for immunotherapy
The NKG2 protein family is mostly expressed on cytotoxic immune cells. They have emerged as new and exciting targets for the development of immune checkpoint modulators in immunotherapy.
Stay updated with breaking news from Mouse Igg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The NKG2 protein family is mostly expressed on cytotoxic immune cells. They have emerged as new and exciting targets for the development of immune checkpoint modulators in immunotherapy.
A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.
CAR-T Therapy: Combating Cytokine Release Syndrome Sponsored Content by ACROBiosystemsMay 21 2021 CAR-T cell therapy offers the hope of a cure to a number of cancer patients. Yet, in spite of the great effectiveness, more attention has been paid to the toxicity of the therapy known as cytokine release syndrome (CRS). This article is aimed at summarizing the main points of assessment, grading and management of CRS in CAR-T Therapy and provide answers to the following questions: How to identify the onset of CRS clinically? What is CRS management? How to use tocilizumab in CRS management? Asse...